This is remarkable since cHL, also due to recurrent alterations of the 9p24.1 chromosomal region, which contains the PD-L1 and PD-L2 loci, is among the human malignancies most responsive to PD-1/PD-L1-targeted immunotherapies [7–9]. This evidence concerns the gene CD274 and classic Hodgkin lymphoma.